Hyloris Pharmaceuticals SA Logo

Hyloris Pharmaceuticals SA

A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.

HYL | BR

Overview

Corporate Details

ISIN(s):
BE0974363955
LEI:
875500LZIWS7QEQE0I73
Country:
Belgium
Address:
Boulevard de Patience et Beaujonc 3, 4000 Liège
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's core strategy involves reformulating and repurposing established drugs by leveraging abbreviated regulatory pathways, such as the U.S. FDA's 505(b)(2) framework. This approach aims to reduce development timelines, costs, and risks. Hyloris has built a broad, patented portfolio of value-added medicines designed to offer significant improvements for patients, healthcare professionals, and payors. Its commercialized products include Sotalol IV for atrial fibrillation and Maxigesic® IV, a non-opioid post-operative pain treatment. The company also develops and markets high-barrier generic products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 00:07
Earnings Release
PR Half Year Results 2025_EN final.pdf
English 392.0 KB
2025-09-25 00:07
Earnings Release
PR Half Year Results 2025_FR final.pdf
French 317.6 KB
2025-09-25 00:07
Earnings Release
PR Half Year Results 2025_EN final.pdf
English 392.0 KB
2025-09-25 00:07
Earnings Release
PR Half Year Results 2025_FR final.pdf
French 317.6 KB
2025-09-25 00:07
Interim Report
2025 06 30 Hyloris HY report_EN final.pdf
English 1.3 MB
2025-09-25 00:07
Interim Report
2025 06 30 Hyloris HY report_FR final.pdf
French 978.2 KB
2025-08-22 07:00
M&A Activity
Press Release Hyloris Signs XTRAZA Licensing Agreement with HUONS.pdf
English 206.8 KB
2025-08-22 07:00
M&A Activity
PR Hyloris Signs XTRAZA Licensing Agreement with Huons FR.pdf
French 221.6 KB
2025-07-17 07:00
Regulatory News Service
Press Release_ Atomoxetine Clinical Trial_EN.pdf
English 221.8 KB
2025-07-17 07:00
Regulatory News Service
Press Release_Atomoxetine Clinical Trial_FR.pdf
French 248.2 KB
2025-07-17 07:00
Regulatory News Service
Press Release_ Atomoxetine Clinical Trial_EN.pdf
English 221.8 KB
2025-07-17 07:00
Regulatory News Service
Press Release_Atomoxetine Clinical Trial_FR.pdf
French 248.2 KB
2025-06-23 07:00
M&A Activity
PR Hyloris_Kuvatris Therapeutics_Partnership EN.pdf
English 251.4 KB
2025-06-23 07:00
Share Issue/Capital Change
PR Hyloris_Kuvatris Therapeutics_Partenariat FR.pdf
French 289.9 KB
2025-06-10 20:00
Post-Annual General Meeting Information
PR AGM 2025 - Hyloris EN.pdf
English 140.7 KB

Automate Your Workflow. Get a real-time feed of all Hyloris Pharmaceuticals SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hyloris Pharmaceuticals SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-13 Aichhorn Dietmar Executive member Buy 12,500 144,375.00 EUR
2023-06-13 Vandebroek Jean-Luc Executive member Buy 6,000 69,300.00 EUR
2022-04-14 Van der Elst Koenraad Executive member Sell 3,312 56,466.40 EUR
2022-03-22 Aichhorn Dietmar Executive member Buy 20,000 347,000.00 EUR
2022-03-22 Vandebroek Jean-Luc Board Buy 3,000 52,050.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.